Find disease awareness content and relevant supporting materials
Adverum Biotechnologies provides update on the INFINITY trial evaluating ADVM 022 in patients with diabetic macular edema.
Adverum Biotechnologies, Inc. announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM 022 gene therapy for the treatment of diabetic macular edema (DME).
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.
Structural retinal imaging biomarkers are important for early recognition and monitoring of inflammation and neurodegeneration in multiple sclerosis. With the introduction of spectral domain optical coherence tomography (SD-OCT)...
Cone dystrophy with supernormal rod responses: A rare KCNV2 gene variant
Purpose: To describe the clinical, electrophysiological, and genetic findings of three Portuguese families with a rare variant in the KCNV2 gene resulting in "cone dystrophy with supernormal rod responses" (CDSRR).